Oscar Health’s (OSCR) “Equal Weight” Rating Reiterated at Stephens

Stephens restated their equal weight rating on shares of Oscar Health (NYSE:OSCR) in a research report sent to investors on Thursday,Benzinga reports. They currently have a $34.00 price target on the stock.

Several other research analysts have also issued reports on OSCR. Wells Fargo & Company raised their target price on shares of Oscar Health from $20.00 to $27.00 and gave the company an “equal weight” rating in a research note on Thursday, August 13th. UBS Group boosted their price target on shares of Oscar Health from $20.00 to $26.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Weiss Ratings upgraded shares of Oscar Health from a “sell (d+)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Wall Street Zen raised shares of Oscar Health from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 14th. Finally, Bank of America lifted their target price on shares of Oscar Health from $28.00 to $30.00 and gave the stock an “underperform” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $33.90.

Oscar Health Trading Up 0.5%

Shares of OSCR opened at $32.14 on Thursday. The stock’s fifty day simple moving average is $30.75 and its 200-day simple moving average is $24.02. The firm has a market capitalization of $9.92 billion, a PE ratio of 22.96, a price-to-earnings-growth ratio of 0.46 and a beta of 2.37. Oscar Health has a 12-month low of $10.69 and a 12-month high of $34.48. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.21.

Oscar Health (NYSE:OSCR) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.10 EPS for the quarter, topping analysts’ consensus estimates of $0.40 by $0.70. The firm had revenue of $4.88 billion during the quarter, compared to analyst estimates of $4.73 billion. Oscar Health had a return on equity of 38.45% and a net margin of 3.60%.The company’s revenue was up 70.4% on a year-over-year basis. During the same period last year, the company earned ($0.89) earnings per share. As a group, research analysts predict that Oscar Health will post 1.74 earnings per share for the current year.

Insider Transactions at Oscar Health

In related news, Director Mario Schlosser sold 880,000 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $29.38, for a total transaction of $25,854,400.00. Following the sale, the director owned 480,866 shares of the company’s stock, valued at approximately $14,127,843.08. This trade represents a 64.66% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Richard Blackley sold 28,869 shares of Oscar Health stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $31.45, for a total value of $907,930.05. Following the transaction, the chief financial officer owned 1,046,108 shares in the company, valued at approximately $32,900,096.60. This represents a 2.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 4,322,257 shares of company stock valued at $126,818,346 over the last three months. 22.64% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Oscar Health

A number of hedge funds have recently modified their holdings of OSCR. BIT Capital GmbH lifted its holdings in shares of Oscar Health by 545.0% during the 4th quarter. BIT Capital GmbH now owns 6,186,267 shares of the company’s stock valued at $88,897,000 after purchasing an additional 5,227,152 shares in the last quarter. Geode Capital Management LLC increased its stake in Oscar Health by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 4,798,313 shares of the company’s stock worth $68,964,000 after purchasing an additional 116,430 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Oscar Health by 22.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,192,777 shares of the company’s stock worth $48,078,000 after purchasing an additional 759,837 shares in the last quarter. Bank of America Corp DE raised its holdings in Oscar Health by 205.1% during the 1st quarter. Bank of America Corp DE now owns 2,860,310 shares of the company’s stock worth $32,808,000 after buying an additional 1,922,732 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in Oscar Health by 1.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,247,992 shares of the company’s stock worth $35,593,000 after buying an additional 20,189 shares during the period. Institutional investors and hedge funds own 75.70% of the company’s stock.

Key Oscar Health News

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Momentum and valuation support investor interest: Zacks identified Oscar Health as a potential “bargain” stock, citing its fast-paced share-price momentum alongside what it considers a reasonable valuation. Oscar was also included in Zacks’ Rank #1 (Strong Buy) growth-stock list. Despite Fast-paced Momentum, Oscar Health Is Still a Bargain Stock
• Positive Sentiment: ACA expansion provides a long-term growth catalyst: Oscar plans a major Obamacare expansion over the next three years. The strategy could increase membership and revenue, building on the company’s recent strong growth and improved profitability. Oscar Health Plans Major Obamacare Expansion Over Next Three Years
• Positive Sentiment: UBS sees meaningful longer-term potential: UBS said its 2029 outlook for Oscar is supported by solid revenue growth, reinforcing the bullish long-range investment case. Oscar Health’s 2029 Target Predicated on Solid Revenue Growth, UBS Says
• Neutral Sentiment: Analyst views remain mixed: Stephens reaffirmed an Equal Weight rating with a $34 target, while Baird raised its target to $33 but maintained a Neutral rating. These targets imply limited near-term upside and suggest analysts see balanced risk and reward. Analysts’ Opinions Are Mixed on Oscar Health
• Negative Sentiment: Key caveat: Oscar’s ACA-focused growth strategy remains exposed to changing government policy, subsidy conditions and the challenge of maintaining profitable growth as enrollment expands. Oscar Health’s Big ACA Gamble Is Paying Off—Here’s the Caveat

About Oscar Health

Oscar Health, Inc is a technology-focused health insurance company that offers health plans and related services to individuals, families and small businesses in the United States. The company’s primary business is providing Individual and Family plans through the Affordable Care Act marketplaces, along with health insurance options for small-group employers in select markets.

Oscar combines insurance coverage with digital tools designed to help members manage their care. Its offerings include online and mobile enrollment, virtual care, provider search and navigation services, claims and benefits information, and access to care teams.